6915 — Jiangxi Institute of Biological Products Income Statement
0.000.00%
Last trade - 00:00- HK$2.12bn
- HK$1.64bn
- CNY235.41m
Annual income statement for Jiangxi Institute of Biological Products, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 198 | 221 | 235 |
| Cost of Revenue | |||
| Gross Profit | 134 | 155 | 181 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Operating Interest Expense / Income | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 134 | 127 | 126 |
| Operating Profit | 64.3 | 94 | 109 |
| Total Net Non Operating Interest Income / Expense | |||
| Total Net Non Operating Interest Income / Expense | |||
| Net Income Before Taxes | 63.6 | 91.8 | 109 |
| Provision for Income Taxes | |||
| Net Income After Taxes | 55.5 | 75.1 | 94.8 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | 55.5 | 75.1 | 94.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | 55.5 | 75.1 | 94.8 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | 0.142 | 0.222 | 0.297 |